Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 19


Donor choice in haploidentical stem cell transplantation: fetal microchimerism is associated with better outcome in pediatric leukemia patients.

Kruchen A, Stahl T, Gieseke F, Binder TM, Özcan Z, Meisel R, Kreyenberg H, Bader P, Gruhn B, Greil J, Pfeiffer M, Döring M, Handgretinger R, Fehse B, Müller I.

Bone Marrow Transplant. 2015 Oct;50(10):1367-70. doi: 10.1038/bmt.2015.136. Epub 2015 Jun 22. No abstract available.


Human leukocyte antigen DR surface expression on CD14+ monocytes during adverse events after hematopoietic stem cell transplantation.

Döring M, Rohrer KM, Erbacher A, Gieseke F, Schwarze CP, Bader P, Handgretinger R, Hofbeck M, Kerst G.

Ann Hematol. 2015 Feb;94(2):265-73. doi: 10.1007/s00277-014-2185-y. Epub 2014 Aug 13.


The PML domain of PML-RARα blocks senescence to promote leukemia.

Korf K, Wodrich H, Haschke A, Ocampo C, Harder L, Gieseke F, Pollmann A, Dierck K, Prall S, Staege H, Ma H, Horstmann MA, Evans RM, Sternsdorf T.

Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12133-8. doi: 10.1073/pnas.1412944111. Epub 2014 Aug 4.


Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation.

Gieseke F, Kruchen A, Tzaribachev N, Bentzien F, Dominici M, Müller I.

Eur J Immunol. 2013 Oct;43(10):2741-9. doi: 10.1002/eji.201343335. Epub 2013 Jul 23.


Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.

Höchst B, Schildberg FA, Sauerborn P, Gäbel YA, Gevensleben H, Goltz D, Heukamp LC, Türler A, Ballmaier M, Gieseke F, Müller I, Kalff J, Kurts C, Knolle PA, Diehl L.

J Hepatol. 2013 Sep;59(3):528-35. doi: 10.1016/j.jhep.2013.04.033. Epub 2013 May 9.


Siglec-7 tetramers characterize B-cell subpopulations and leukemic blasts.

Gieseke F, Mang P, Viebahn S, Sonntag I, Kruchen A, Erbacher A, Pfeiffer M, Handgretinger R, Müller I.

Eur J Immunol. 2012 Aug;42(8):2176-86. doi: 10.1002/eji.201142298. Epub 2012 Jul 9.


Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity.

Johann PD, Vaegler M, Gieseke F, Mang P, Armeanu-Ebinger S, Kluba T, Handgretinger R, Müller I.

BMC Cancer. 2010 Sep 21;10:501. doi: 10.1186/1471-2407-10-501.


Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells.

Gieseke F, Böhringer J, Bussolari R, Dominici M, Handgretinger R, Müller I.

Blood. 2010 Nov 11;116(19):3770-9. doi: 10.1182/blood-2010-02-270777. Epub 2010 Jul 19.


Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells.

Holzwarth C, Vaegler M, Gieseke F, Pfister SM, Handgretinger R, Kerst G, Müller I.

BMC Cell Biol. 2010 Jan 28;11:11. doi: 10.1186/1471-2121-11-11.


Platelet derived bFGF mediates vascular integrative mechanisms of mesenchymal stem cells in vitro.

Langer HF, Stellos K, Steingen C, Froihofer A, Schönberger T, Krämer B, Bigalke B, May AE, Seizer P, Müller I, Gieseke F, Siegel-Axel D, Meuth SG, Schmidt A, Wendel HP, Müller I, Bloch W, Gawaz M.

J Mol Cell Cardiol. 2009 Aug;47(2):315-25. doi: 10.1016/j.yjmcc.2009.03.011. Epub 2009 Mar 27.


Dendritic cells: functional aspects of glycosylation and lectins.

Erbacher A, Gieseke F, Handgretinger R, Müller I.

Hum Immunol. 2009 May;70(5):308-12. doi: 10.1016/j.humimm.2009.02.005. Epub 2009 Feb 21. Review.


Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1.

Battula VL, Treml S, Bareiss PM, Gieseke F, Roelofs H, de Zwart P, Müller I, Schewe B, Skutella T, Fibbe WE, Kanz L, Bühring HJ.

Haematologica. 2009 Feb;94(2):173-84. doi: 10.3324/haematol.13740. Epub 2008 Dec 9.


Tumor-associated MICA is shed by ADAM proteases.

Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG, Steinle A.

Cancer Res. 2008 Aug 1;68(15):6368-76. doi: 10.1158/0008-5472.CAN-07-6768.


WT1 protein expression in slowly proliferating myeloid leukemic cell lines is scarce throughout the cell cycle with a minimum in G0/G1 phase.

Kerst G, Bergold N, Viebahn S, Gieseke F, Kalinova M, Trka J, Handgretinger R, Müller I.

Leuk Res. 2008 Sep;32(9):1393-9. doi: 10.1016/j.leukres.2008.03.006.


WT1 protein expression in childhood acute leukemia.

Kerst G, Bergold N, Gieseke F, Coustan-Smith E, Lang P, Kalinova M, Handgretinger R, Trka J, Müller I.

Am J Hematol. 2008 May;83(5):382-6.


Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression.

Gieseke F, Schütt B, Viebahn S, Koscielniak E, Friedrich W, Handgretinger R, Müller I.

Blood. 2007 Sep 15;110(6):2197-200. Epub 2007 May 23.


Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM.

Müller I, Kordowich S, Holzwarth C, Spano C, Isensee G, Staiber A, Viebahn S, Gieseke F, Langer H, Gawaz MP, Horwitz EM, Conte P, Handgretinger R, Dominici M.

Cytotherapy. 2006;8(5):437-44.


Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.

Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A.

Blood. 2003 Aug 15;102(4):1389-96. Epub 2003 Apr 24.


A new approach to the treatment of inoperable brain tumors.

Ommaya AK, Rubin RC, Henderson ES, Rall DP, Gieseke FG, Bering EA Jr, Bagan M.

Med Ann Dist Columbia. 1965 Oct;34(10):455-8. No abstract available.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk